Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, David Dodwell, David Cameron, Larry Hayward, Young-hyuck Im, Jeremy P Braybrooke, A Murray Brunt, Kwok-leung Cheung, Rema Jyothirmayi, Anne Robinson, Andrew M Wardley, Duncan Wheatley, Anthony Howell, Gill Coombes, Nicole Sergenson, Hui-jung Sin, Elizabeth Folkerd, Mitch DowsettJudith M Bliss

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)989-998
JournalThe Lancet Oncology
Issue number10
Publication statusPublished - 1 Sep 2013

Cite this